Étiquette : HLA-G

PLENARY SESSION 1 : HLA-G

Chairpersons: Edgardo D. Carosella and Vera Rebmann

• Ouverture du colloque par E.D. Carosella (France)
• Barbara SELIGER (Germany) “Role of HLA-G in tumors and upon COVID-19 infection”

• Anatolij HORUSZKO (USA) “Tolerogenic properties of HLA-G and its receptors in relation to transplant acceptance”
• Nathalie ROUAS-FREISS (France) “HLA-G/ILT2/ILT4 Immune Checkpoint: Function and Clinical Applications”
• Roberta RIZZO (Italy) “Role of HLA-G molecules in SARS-CoV-2 infection »

SYMPOSIUM I : HLA-G IN CANCER

Chairpersons: Joël LEMAOULT, Fabio MORANDI

• Investigating HLA-G for accurate detection of the colorectal cancer risk and prognosis using data science tools : different speeds for meaningful outcomes!Nadia Boujelbene, Marwa Hasni, Sabrine Dhouioui, Kalthoum Tizaoui, Hadda-Imene Ouzari, Safa Bhar Layeb, Inès Zemni, Inès Zidi
• Comprehensive analysis of classical HLA Class I and non classical HLA-F and HLA-G in colon cancerHehuan Zhu, Jessica Rolands, Eiman Ahmed, Wouter Hendrickx, Davide Bedognetti, and Peter J K Kuppen
• Evaluation of the specificity of the 4H84 antibody by bioinformatics methodsKevin Martinez, Fernando Riccillo, Marcela N. Garcia
• Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model with Immune Infiltration for Immunotherapeutic StudiesLeonard Lugand, Guillaume Mestrallet, Rebecca Laboureur, Clement Dumont, Fatiha Bouhidel, Malika Djouadou, Alexandra Masson-Lecomte, Francois Desgrandchamps, Stéphane Culine, Edgardo D. Carosella, Nathalie Rouas-Freiss, Joel LeMaoult
• HLA-G expression in transitional carcinoma of the bladder, in Argentine patients, and its relationship with the level of invasion and survivalDamián Moavro, Pablo Colaci, Marcela N. García

PLENARY SESSION 2

HLA-G IMMUNE FUNCTION

Chairpersons: Nathalie ROUAS-FREISS, Anatolij HORUZSKO

• Silvia GREGORI (Italy) “HLA-G-expressing DC-10 a biomarker of tolerance.”
• Katsumi MAENAKA (Japan) “Structural aspects and antibody binding of HLA-G isoforms”
• Laurence AMIOT (France) « HLA-G is mainly expressed by mast cells in the fibrotic regions of liver, lung and kidney”
•  Fabio MORANDI (Italy) “Interactions between HLA-G and other immune checkpoints”

PLENARY SESSION 3

HLA-G, COVID AND PARASITE INFECTIONS

Chairpersons: Fabio Morandi

• Daria BORTOLOTTI (Italy) « SARS-CoV-2 infection in placental tissues: altered expression of HLA-G molecules”
• Hana ROHN (Germany) “Systematic analysis of HLA-G in COVID-19 disease”
• David COURTIN (France) “LILRB1 and LILRB2 expression and susceptibility to malaria”

SYMPOSIUM II: HLA-G AND DISEASE

Chairpersons: Antoine DURRBACH, Eduardo A. DONADI

• Combined plasma levels of IL-10 and testosterone, but not soluble HLA-G5, predict the risk of death in CONVID-19 patientsGiada Amodio, Paolo Capogrosso, Marina Pontillo, Michela Tassara, Luca Boeri, Cristina Carenzi, Daniele Cignoli, Anna Maria Ferrara, Giuseppe A. Ramirez, Cristina Tresoldi, Massimo Locatelli, Luca Santoleri, Antonella Castagna, Alberto Zangrillo, Francesco De Cobelli, Moreno Tresoldi, Giovanni Landoni, Patrizia Rovere-Querini, Fabio Ciceri, Francesco Montorsi, Andrea Salonia, Silvia Gregori
• Pre-clinical development and characterization of a decitabine-induced regulatory HLA-G + CD4 + -T cell enriched cell product against GVHDM. Lysandrou, D. Kefala, P. Christofi, P.G. Papayanni, C. Pieridou, N. Savvopoulos, A.-L. Chatzidaniil, M. Kyriakou, P. Costeas, A. Papadopoulou, E. Yannaki, A. Spyridonidis
• Wound healing by allogenic transplantation of umbilical cord mesenchymal stem cells in different speciesAilén Iribarne, María Belén Palma, Camila Seoane Rocha, Laura Andrini, Fernando Riccillo, Guillermo Buero, Marcos Torres, Santiago Bruno, Pablo Pelinski, Santiago Miriuka, Edgardo D. Carosella, Marcela N. Garcia
• HLA-G and CD152 expression levels encourage the use of umbilical cord tissue-derived mesenchymal stromal cells as an alternative for immunosuppressive therapyBernardo Zoehler, Letícia Fracaro, Lidiane Maria Boldrini Leite, José Samuel da Silva, Paul Travers, Paulo Roberto Slud Brofman, Alexandra Cristina Senegaglia and Maria da Graça Bicalho
• HLA-J, a non-pseudogene as a new prognostic marker for therapy response and survival in breast cancerWürfel FM, Wirtz RM, Winterhalter C, Taffurelli M, Santini D, Mandrioli A, Veltrup E, Ruebner M, Fasching PA, Würfel W, Zamagni C
• 17:40 HLA I class expression as a new prognostic marker of successful implantationMargarita Shengelia, Bespalova O, Ivashchenko T

PLENARY SESSION 4

HLA-G IN CANCER

Chairpersons: Silvia GREGORI, François DESGRANDCHAMPS

• Vera REBMANN(Germany) “The clinical relevance of soluble HLA-G and HLA-G bearing extracellular vesicles in breast cancer and their potential to modulate T cell phenotypes”
• Diana LE ROUX(France) “HLA-G isoforms and their new role in tumours development”
• Christophe HENNEQUIN (France) “Immuno and Radiotherapy”

• Joël LE MAOULT (France) “ILT2-expressing cells in urologic cancers”

 SYMPOSIUM III: HLA-G IN ALLOGRAFT AND MSC

Chairpersons:  Vera REBMANN, Diego DELGADO

• HLA-G gene editing in tumor cell lines as a novel tool in cancer therapies
  María Belén Palma, Diana Tronik-Le Roux, Camila Seoane Rocha, Ailen Iribarne, Alejandro La Greca, Lucía N. Moro, Marina Daouya, Isabelle Poras, Edgardo D. Carosella, Marcela N. García, Santiago G. Miriuka
• Redirection of immune cells specificity against HLA-G: anti HLA-G CAR T cellsMarie Escande, Espie David, Anna François, Giroux Benoit, Lecomte Martin, Langlade-Demoyen Pierre, Donnadieu Emmanuel, Loustau Maria, Caumartin Julien
• ILT2-positive CD8+ T cells in clear-cell renal cell carcinoma: potential implications for cancer immunotherapyC. Dumont, L. Lugand, R. Laboureur, J. Vérine, A. Masson-Lecomte, S. Culine, F. Desgandschamps, E.D. Carosella, J. LeMaoult, N. Rouas-Freiss
• Cytotoxic functions of CD8+ ILT2+ cells in clear cell renal cell carcinomaRebecca Laboureur, Léonard Lugand, Clément Dumont, Fatiha Bouhidel, Malika Djouadou, François Desgandschamps, Alexandra Masson-Lecomte, Edgardo D. Carosella, Joël LeMaoult, Nathalie Rouas-Freiss
• Advances in cancer immunotherapy development:new VHH-based immune checkpoint inhibitors targeting the receptor ILT4Raphaëlle Dréan, Gabriel Aymé, Alix Jaquier, Odessa Fayet, Martin Lecomte, Julien Caumartin, Maria Loustau, Pierre Lafaye

PLENARY SESSION 5

HLA-G IN PREGNANCY AND TRANSPLANTATION

Chairperson:  Diego DELGADO

•  Michael EIKMANS (Netherlands) “The role of HLA-G in women with recurrent pregnancy loss”
• Thomas Vauvert F. HVIID (Denmark) “An update on HLA-G and HLA-F in reproduction”
• Olivier BRUGIÈRE (France) “Prediction of chronic lung allograft dysfunction by measurement of circulating cytotoxic CD4+CD57+ILT2+ T cells, selectively inhibited by the immune check-point HLA-G”

PLENARY SESSION 6

HLA-G, REGULATION AND EXPRESSION

Chairpersons: Philippe MOREAU, Thomas V.F. HVIID

• Eduardo A. DONADI (Brazil) “Atomistic studies on HLA-G: major isoforms and interactions with receptors and with transcription factor” 
• Julie DI CRISTOFARO (France) “HLA 1b haplotype, from clinics to genetic evolution”
• Antonio ARNAIZ-VILLENA(Spain) « Evolution of HLA-G, HLA-haplotypes and disease association”
• Erick CASTELLI (Brazil) « HLA-G worldwide genetic diversity and evolutionary aspects« 

Closing remarks by Anatolij HORUSZKO